Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProSomnus, Inc. - Common Stock (NQ: OSA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProSomnus, Inc. - Common Stock

< Previous 1 2 Next >
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
Additional clinical research indicates patients using ProSomnus devices have decreased apnea-hypopnea index events per hour, with strong treatment adherence 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
Record quarterly revenue of $7.1 million represents an increase of 41.5% year-over-year and seventh consecutive quarter of sequential revenue growth 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Participation in the 2023 Roth Capital Healthcare Opportunities Conference
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Raises $10 Million To Fuel Growth and Optimize Operations
Company will leverage new capital inflow to optimize core business operations, advance strategic growth initiatives, and achieve cash flow breakeven 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Precision Obstructive Sleep Apnea Devices to be Featured in Scientific Abstracts and Podium Presentations at Upcoming Medical Conferences
Scientific Abstracts and Presentations Feature New and Additional Data Demonstrating the Efficacy, Effectiveness, and Safety of ProSomnus Precision Devices for the Treatment of Obstructive Sleep Apnea 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Updated Clinical Trial Data Indicates Precision Oral Appliance Therapy with ProSomnus Devices is Non-Inferior to CPAP Therapy for the Treatment of Moderate to Severe Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus to Design Head-to-Head Clinical Trial vs. Hypoglossal Nerve Stimulation
Preliminary severe Obstructive Sleep Apnea data from FLOSAT study indicates opportunity for head-to-head trial between precision oral appliance therapy and hypoglossal nerve stimulation 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
71% of Self-identified Snorers Have Never Consulted a Healthcare Professional
National survey identifies major obstacles to treating snoring and sleep issues 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 SLEEP Annual Meeting Strengthens Evidence for ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports First Quarter 2023 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Announces Q1 2023 Investor Call and Participation in Upcoming Investor Conferences
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
Study to be Presented at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference Demonstrates Efficacy of ProSomnus Precision Oral Appliances
Study data indicates that ProSomnus precision oral appliances appear to be more efficacious than traditional oral appliances for the treatment of mild, moderate, and severe Obstructive Sleep Apnea 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Announces Publication of Four Accepted Abstracts in the Journal of Dental Sleep Medicine in Advance of Annual Meeting
Study results to be presented in oral and poster presentations at 2023 American Academy of Dental Sleep Medicine Annual Meeting 
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Receives Additional U.S. Utility Patent Covering Iterative Titration Technology for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Receives Patent Allowance Covering Automated Manufacturing Process for Company’s Novel Precision Sleep Apnea Medical Devices
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus to Host Investor Call and Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus® Announces Acceptance of Abstract at European Respiratory Society and European Sleep Research Society’s Sleep and Breathing 2023 Conference
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
ProSomnus to Present at Two Upcoming Investor Conferences in March 2023
From ProSomnus Sleep Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.